In the rush to produce mRNA vaccines and ensure integrity and purity, capital-intensive purification steps were used, typically involving slow diffusion-driven, inefficient, and costly chromatographic resin processes. We present the first results that microporous affinity synthetic polymer membranes can outperform commercial monolithic and resin approaches for capture of mRNA, thereby promoting fast purification of mRNA vaccines and therapeutics. Our seminal finding is that capture of Fluc-mRNA by synthetic affinity membranes enables efficient intact mRNA recovery (∼100 % of bound mass), faster processing times and lower dispersion by leveraging convective flow with short diffusional path lengths. We also demonstrate higher ligand accessibility and device productivity. Accessible ligand per device volume was 87–94 %, ∼74 % and ∼53 % for the membranes, monoliths, and resin column, respectively. A calibrated mathematical framework predicted mRNA pulse breakthrough with dispersion that was measured in the process tubing and membrane module using a non-reactive tracer and modeled using ideal reactors.